UNSPSC 51263152: Bisoprolol hemifumarate

This classification denotes a beta-adrenergic blocking agent with the molecular formula 2C18H31NO4.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UR59KN573L, chemically known as 2-propanol, 1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino)-, (+/-)-, (e)-2-butenedioate (2:1) (salt), but more generally known as bisoprolol hemifumarate, which bears US NIH Compound Identifier 2405.

European Medicines Agency schedules bisoprolol hemifumarate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13096MIG. Most nations, for tariff purposes, schedule bisoprolol hemifumarate under HS 29221980. SMILES: CC(C)NCC(COC1CCC(CC1)COCCOC(C)C)O.CC(C)NCC(COC1CCC(CC1)COCCOC(C)C)O.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51263152 Bisoprolol hemifumarate is a Commodity code that nominally addresses a specific beta-blocker pharmaceutical, but recent state and local procurement activity under this code shows a marked mismatch: the single recent opportunity on record is Seminole County, Florida's IFB60459723LAS, released June 30, 2026, which solicits naloxone and safe drug deactivation systems rather than bisoprolol. The mismatch suggests either a tagging error in the state or local procurement system or a broad misapplication of the code to cover emergency-response pharmaceuticals and harm-reduction equipment more broadly than the code's nominal scope would indicate.

Seminole County, a Florida county government, is the sole issuing body with recent activity under this code. The IFB sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with response due July 26, 2023, on a fixed-fee basis and an initial two-year term with one-year renewal option. The procurement required E-Verify compliance, drug-free workplace certification, and workers' compensation and general liability insurance, and potentially carried FEMA funding with associated federal compliance obligations. Given the single opportunity and the clear divergence between the code name and the actual work being solicited, this code shows little relevant recent activity for pharmaceutical procurement.